<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330926</url>
  </required_header>
  <id_info>
    <org_study_id>MENAC-2013-05</org_study_id>
    <secondary_id>2013-002282-19</secondary_id>
    <nct_id>NCT02330926</nct_id>
  </id_info>
  <brief_title>Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy</brief_title>
  <acronym>MENAC</acronym>
  <official_title>A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Regional Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Beatson West of Scotland Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Margaret Hospital, Dunfermline</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK Edinburgh Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malteser Krankenhaus Seliger Gerhardt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tumor Biology Center Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tumor Zentrum Aarau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle
      mass (with or without loss of fat mass) that cannot be fully reversed by conventional
      nutritional support and leads to progressive functional impairment.

      There is an urgency for improving management, but there is no consensus on the optimal
      treatment for cancer cachexia. Several single therapies for cancer cachexia have been
      examined in clinical trials, with disappointing overall results. As multiple factors are
      responsible for the development of cachexia, it has been argued that optimal cachexia
      interventions should target all components: multimodal therapy for a multimodal problem.

      The overall aim of this study is to early prevent the development of cachexia rather than
      treatment late in the disease trajectory. From a patient perspective a short term effect will
      be to improve physical and psychological function, to reduce symptom burden and to improve
      survival. In other words live a longer and better life during and after chemotherapy. Direct
      effects of the cachexia intervention are expected to be reduction of weight and muscle loss,
      and improved physical activity and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in body weight</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in muscle mass</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in physical activity</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cachexia</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>multimodal intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard palliative care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutritional supplements and advice</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>home-based self-assisted exercise program</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of lung cancer, pancreatic cancer or cholangiocarcinoma where the diagnosis
             is based on histological, radiological or multidisciplinary team (MDT) evaluation

          -  non-small cell lung cancer (stage III or IV), small cell lung cancer (extensive stage)
             or pancreatic adenocarcinoma (stage III or IV) or non-operable cholangiocarcinoma, due
             to commence first or second line anticancer treatment (defined as chemotherapy or
             chemo-radiotherapy or targeted therapy

          -  staging CT within 4 weeks of commencement of anti-cancer therapy (in patients where
             staging CT is out-with this period, further CT scanning will be undertaken. PETCT's
             are also appropriate)

          -  completed all other baseline assessments within one week prior to first course of
             anti-cancer treatment

          -  written informed consent

          -  able to comply with trial interventions (in the opinion of referring clinician) e.g.
             willing and able to do light exercise and take oral nutritional supplements as well as
             no major contraindications against ibuprofen.

          -  Karnofsky Performance Status &gt;70

        Exclusion Criteria:

          -  Neuro-endocrine pancreatic cancer

          -  Creatinine clearance &lt;30ml/min

          -  Receiving parenteral nutrition or enteral nutrition via feeding tube

          -  receiving neo-adjuvant anti-cancer therapy

          -  BMI &gt;30 kg/m2

          -  Use of appetite stimulants or anabolic/anti-catabolic agents (such as megestrol
             acetate, progestational agents, marijuana growth hormone, dronabinol, or other
             anabolic agent) within 30 days prior to study baseline

          -  Concomitant steroid (&gt;10mg/d prednisolone or equivalent) treatment for less than three
             months prior to inclusion (inhaled, optical or pulsed oral steroids (up to 10 days
             use) are permitted)

          -  Concomitant long term (&gt;1 week) nonsteroidal anti-inflammatory drugs (NSAID) or
             aspirin treatment

          -  pregnancy, breast-feeding or of child bearing potential (that is not postmenopausal or
             permanently sterilised) age and not using adequate contraception (oral, injected,
             implanted or hormonal methods of contraception, intrauterine device and barrier
             method)

          -  Concomitant anti-coagulant treatment (e.g. warfarin or heparin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Kaasa, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>European Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU, Trondheim, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Fallon, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trude R Balstad, PhD</last_name>
    <email>trude.r.balstad@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tora S Solheim, MD PhD</last_name>
    <email>tora.l.skeidsvoll@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cross Cancer Insitute</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meri-Jo Thompson</last_name>
      <email>methompson@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Quincy Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meri-Jo Thompson</last_name>
      <email>methompson@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Thomas Jagoe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meri-Jo Thompson</last_name>
      <email>methompson@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Thimothy Asmis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Wolber</last_name>
      <email>Uta.Wolber@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Lukas Radbruch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asta Bye, PhD</last_name>
      <email>asta.bye@hioa.no</email>
    </contact>
    <investigator>
      <last_name>Nina Aass, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trude R Balstad, PhD</last_name>
      <email>trude.r.balstad@ntnu.no</email>
    </contact>
    <contact_backup>
      <last_name>Inger Storaker, M.Sc.</last_name>
      <email>inger.storaker@ntnu.no</email>
    </contact_backup>
    <investigator>
      <last_name>Tora S Solheim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumor Zentrum</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Kälin</last_name>
      <email>Simone.Kaelin@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Gabriela Popescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Razavan Popescu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Kälin</last_name>
      <email>Simone.Kaelin@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Florian Strasser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ackermann Christoph, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Llandough Hospital</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@soton.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@ac.soton.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Barry Laird, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Margaret Hospital</name>
      <address>
        <city>Fife</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacke Madden</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@ac.soton.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Joanna Bowden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@soton.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Janet Graham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nick Gough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, Strasser F, Griffiths G, Maddocks M, Fallon M, Kaasa S, Fearon K. Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018 Feb 9. pii: bmjspcare-2017-001440. doi: 10.1136/bmjspcare-2017-001440. [Epub ahead of print] Review.</citation>
    <PMID>29440149</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2014</study_first_submitted>
  <study_first_submitted_qc>January 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combined modality treatment</keyword>
  <keyword>Diet therapy</keyword>
  <keyword>Exercise therapy</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Dietary supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

